Low-Dose⁣ Atropine ⁢for Myopia⁣ Control: New Study Raises Questions About⁣ Long-Term Safety

New York, NY – A large, retrospective ⁢study published today in ⁣ JAMA Ophthalmology offers ‌a nuanced look at the ‌safety of low-dose atropine eye drops, ⁣a treatment increasingly used to slow the ‍progression of nearsightedness (myopia)⁢ in children. While the study found no overall difference in common‌ ocular complications like glaucoma and ⁤cataracts between children treated with atropine and those ‌who weren’t,‍ it⁣ did suggest a potential link between longer-term use and increased risk – a ⁤finding⁢ researchers say ‌warrants further investigation.

Myopia is⁣ a⁣ growing global health concern, especially in East Asia, where rates are soaring. ⁣ Left unchecked, increasing myopia isn’t ‌just a matter of needing stronger glasses; it substantially‌ elevates the risk of serious, possibly vision-threatening⁢ conditions like‌ myopic maculopathy,⁤ open-angle glaucoma,⁢ and ⁤retinal detachment.

Atropine drops work by temporarily dilating the pupil and relaxing the focusing muscles of the‍ eye. ‌ Research has indicated that, at low doses, these ⁤drops‍ can⁤ effectively slow⁣ myopia progression​ – leading to​ widespread adoption in⁢ countries like Taiwan, where they’ve been ⁢used for over two decades.

Study ‍Details & ⁤Key Findings

Researchers led ⁣by​ Dr. Tzu-Hsun Tsai of National Taiwan University Hospital analyzed data ⁢from Taiwan’s National Health Insurance program, encompassing nearly ‍600,000‌ children aged 8-15 ‍diagnosed with myopia between‍ 2001 and 2015. Approximately two-thirds of‌ these children were treated ⁢with atropine drops, while⁣ the remaining third were not. The study boasted a significant follow-up period, with over ‍70% of participants tracked for‍ 10 ⁣years ⁢and⁢ 40% for 15 years.

The study ‍focused on ‌the incidence of cataracts, ‍glaucoma, and maculopathy. While children with myopia had ​a roughly⁣ 50%​ greater risk of developing​ these conditions compared to those without myopia (consistent with existing research),the analysis of atropine use yielded mixed results.⁣

Initially, longer-term atropine prescription appeared associated with ⁢a higher‌ risk of ocular complications. However, this association ⁤weakened when researchers accounted for the severity of ‍the children’s ⁢myopia. Crucially,​ the ⁢ cumulative ​dose of atropine ⁢- the ⁣total amount used over time – wasn’t linked to⁣ a greater risk, suggesting duration of use, rather than total exposure, might potentially ‌be ⁢the more significant factor.

What Dose This Mean for Parents?

“This study doesn’t ‌necessarily mean atropine is unsafe,” explains Dr. Michael Lee, Editor-in-Chief‍ at world-today-news.com.⁤ “It highlights the need ‌for‍ careful monitoring and​ a personalized approach to‌ myopia ‍management.The findings suggest that ⁣while atropine appears generally safe,​ clinicians should be mindful of long-term use and consider the ‌individual patient’s myopia severity.”

The researchers themselves acknowledge that the increased risk observed with longer-term‍ use‌ may be⁣ linked⁢ to the underlying severity⁣ of ⁢myopia, rather than ⁢the drops themselves. More research is needed⁣ to definitively clarify this relationship.

Looking Ahead

This ‍study underscores the importance of ongoing research into the long-term effects of myopia control strategies. As the global​ prevalence of myopia continues ‍to rise, understanding the ⁢benefits and‍ risks of⁢ treatments like low-dose atropine is crucial for protecting the vision⁤ of future generations.

Sources:

* Tsai,T. H., et al. ⁣(2024). Association of Atropine Use With Ocular Complications⁣ Among Children With Myopia. JAMA ‌Ophthalmology. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2838641

* JAMA Network: https://jamanetwork.com/

SEO Keywords: ‌myopia, nearsightedness, atropine, eye drops, children, vision, glaucoma, ‌cataracts, ⁢maculopathy, eye health, ophthalmology, myopia control,⁣ vision correction.

Here’s a breakdown of the provided text, focusing on the key information about CAR T-cell therapy for autoimmune diseases:

What is CAR T-cell Therapy?

Type of Immunotherapy: It’s a treatment that uses a patient’s own immune cells.
how it effectively works:
T-cells are extracted from the patient’s blood.
These T-cells are genetically modified in a lab to target specific cells.
The modified T-cells are multiplied.
The modified T-cells are then reinfused into the patient. Original Use: Typically used to treat blood cancers like lymphoma.

The Connection: Both lymphoma and autoimmune diseases affect a patient’s B cells.
In lymphoma, B cells become cancerous. In autoimmune diseases, B cells produce antibodies that attack the body’s own cells.
The Target: The therapy being tested uses CAR T-cells to target the CD19 protein, which is found on the surface of B cells.
The Outcome: Researchers have found that this therapy can eliminate autoimmune antibodies and allow the patient’s B cells to regenerate healthily.
Potential Impact: If trials continue to be positive, it coudl lead to a cure for autoimmune diseases with a single infusion.

Participating Centers: 40 centers in the US and Europe are testing this therapy for autoimmune diseases.
University of Miami Miller School of Medicine (Sylvester Complete Cancer center):
Is testing the therapy on patients with lupus,scleroderma,and polymyositis.
Has already treated a scleroderma patient for neurological side effects. Will soon begin treating another scleroderma patient.
Will soon start a second trial specifically for lupus patients.
Future Interest: Researchers are also interested in using CAR T-cell therapy for neurological autoimmune disorders like multiple sclerosis.

Expert Opinion:

Dr. Damian Green: Highlights that this is a meaningful point where advancements in cancer therapy are translating to othre serious ailments. He emphasizes the “tremendous opportunity” to help patients with life-threatening autoimmune conditions.
Patient Generosity: Dr.Green credits the success of the trials to the generosity of cancer patients who volunteered,understanding that their participation might not directly benefit them but could help a much broader population.

In essence, the article describes a groundbreaking shift in the application of CAR T-cell therapy, moving from cancer treatment to potentially curing autoimmune diseases by targeting and eliminating the problematic B cells responsible for the autoimmune response.